Published • loading... • Updated
Lupin’s Ankleshwar facility receives EIR from US FDA
Summary by Express Pharma
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Lupin’s Ankleshwar facility receives EIR from US FDA
Global pharma major Lupin announced that it has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (US FDA) for its Ankleshwar facility in Gujarat, India, following closure of a product- specific Pre-Approval Inspection from March 2 to March 7, 2026. Nilesh Gupta, Managing Director, Lupin, stated, “We are pleased to receive the EIR from the US FDA for our Ankleshwar facility. This outcome refle…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
